Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia
Bitter, Istvan, Lieberman, Jeffrey A., Gaudoux, Florence, Sokoloff, Pierre, Groc, Mélanie, Chavda, Rajeev, Delsol, Cécile, Barthe, Laurence, Brunner, Valérie, Fabre, Carine, Fagard, Marine, Montagne,Journal:
Neuropsychopharmacology
DOI:
10.1038/s41386-019-0355-2
Date:
March, 2019
File:
PDF, 764 KB
2019
File converter
More search results
More benefits 
